Our BoardCommNexus is a non-profit organization that is member supported. We rely on the sponsorship of industry companies, along with the participation of individuals from our community, to assist us in helping the San Diego technology community. Our Board of Directors is comprised of representatives from our sponsor companies and industry advisors.
At the heart of EvoNexus is a driven team working tirelessly to ensure EvoNexus provides startups with the support and opportunities needed to prosper and pioneer the future of technology.
Dr. Marcus F. Boehm
EvoNexus San Diego Committee
Co-Founder & Former CTO, Receptos
Dr. Marcus F. Boehm has worked in the biotechnology community for over 25 years. Most recently, he was a Co-Founder of Receptos Inc. where he served as Chief Technology Officer and Vice President of Chemistry from 2009 to 2015 until its acquisition by Celgene Corporation. As a member of the executive management team, he shared responsibility for the development of ozanimod for treatment of multiple sclerosis and ulcerative colitis, and RPC4046 for treatment of eosinophilic esophagitis. He also led early discovery research and development programs, chemical manufacturing and controls, and supported corporate financing and partnering activities. In 2007, Dr. Boehm co- founded Apoptos Inc. and served as the Vice President of Chemistry until it was acquired by Receptos in May 2009. In 2001 Dr. Boehm was a founding member of Conforma Therapeutics, which was acquired by Biogen Idec in 2006. As Vice President of Chemistry at Conforma, he led a team that discovered and developed CNF2024 for treatment of solid tumors. At Biogen Idec, he served as the head of chemistry for the San Diego site from 2006-2007 with responsibility for multiple medicinal chemistry programs. Dr. Boehm started his industry career with Ligand Pharmaceuticals in 1991 where he held various positions with progressing responsibility. He led chemistry efforts on multiple intracellular receptor (IRs) programs resulting in the discovery and development of Targretin for T-cell lymphomas and Panretin for treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. He is a co-author and inventor on over 100 patents and publications in the area of oncology, autoimmune and metabolic diseases. He has consulted for private venture capital firms and start-up biotech companies and continues to assist them to identify new investments and develop programs. Dr. Boehm received a B.A. in Chemistry from the University of California, San Diego, a Ph.D. in Chemistry from the State University of New York Stony Brook and completed a National Institutes of Health Postdoctoral Fellowship at Columbia University.